212 related articles for article (PubMed ID: 25327841)
21. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
22. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
Mikesch JH; Kuhlmann M; Demant A; Krug U; Thoennissen GB; Schmidt E; Kessler T; Schliemann C; Pohlen M; Mohr M; Evers G; Köhler G; Wessling J; Mesters R; Müller-Tidow C; Berdel WE; Thoennissen NH
Ann Hematol; 2013 Aug; 92(8):1041-8. PubMed ID: 23532626
[TBL] [Abstract][Full Text] [Related]
23. Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis.
Mozessohn L; Cheung MC; Crump M; Buckstein R; Berinstein N; Imrie K; Kuruvilla J; Piliotis E; Kukreti V
Leuk Lymphoma; 2014 Nov; 55(11):2502-7. PubMed ID: 24450580
[TBL] [Abstract][Full Text] [Related]
24. Rituximab maintenance therapy until progression after rituximab and chemotherapy induction in patients with follicular lymphoma.
Yared J; Kimball A; Baer MR; Bahrain H; Auerbach M
Clin Lymphoma Myeloma Leuk; 2013 Jun; 13(3):253-7. PubMed ID: 23352637
[TBL] [Abstract][Full Text] [Related]
25. Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi.
Anastasia A; Carlo-Stella C; Corradini P; Salvi F; Rusconi C; Pulsoni A; Hohaus S; Pregno P; Viviani S; Brusamolino E; Luminari S; Giordano L; Santoro A
Br J Haematol; 2014 Jul; 166(1):140-2. PubMed ID: 24606548
[No Abstract] [Full Text] [Related]
26. Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study.
Witzens-Harig M; Foá R; Di Rocco A; van Hazel G; Chamone DF; Rowe JM; Arcaini L; Poddubnaya I; Ho AD; Ivanova V; Vranovsky A; Thurley D; Oertel S
Ann Hematol; 2014 Oct; 93(10):1717-24. PubMed ID: 24824768
[TBL] [Abstract][Full Text] [Related]
27. Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma.
Luminari S; Marcheselli L; Sacchi S; Pozzi S; Bari A; Ilariucci F; Stelitano C; Angrilli F; Lazzaro A; Baldini L
Cancer; 2009 May; 115(9):1906-13. PubMed ID: 19248044
[TBL] [Abstract][Full Text] [Related]
28. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.
Papageorgiou SG; Diamantopoulos P; Levidou G; Angelopoulou MK; Economopoulou P; Efthimiou A; Constantinou N; Katsigiannis A; Korkolopoulou P; Pappa V; Economopoulou C; Georgiou G; Dimou M; Tsirigotis P; Kyrtsonis MC; Kotsianidis I; Kalpadakis C; Dimopoulos MA; Beris P; Meletis J; Pangalis GA; Dervenoulas J; Panayiotidis P; Vassilakopoulos TP
Hematol Oncol; 2013 Mar; 31(1):10-7. PubMed ID: 22610484
[TBL] [Abstract][Full Text] [Related]
29. Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab.
Coiffier B; Li W; Henitz ED; Karkera JD; Favis R; Gaffney D; Shapiro A; Theocharous P; Elsayed YA; van de Velde H; Schaffer ME; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Romejko-Jarosinska J; de Vos S; Crump M; Shpilberg O; Zinzani PL; Cakana A; Esseltine DL; Mulligan G; Ricci D
Clin Cancer Res; 2013 May; 19(9):2551-61. PubMed ID: 23549871
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy: maintenance rituximab for relapsed follicular lymphoma.
Wrench D; Montoto S
Nat Rev Clin Oncol; 2010 Dec; 7(12):677-8. PubMed ID: 21116237
[No Abstract] [Full Text] [Related]
31. Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL).
Rusconi C; Anastasia A; Chiarenza A; Marcheselli L; Cavallo F; Rattotti S; Botto B; Ferrari A; Nassi L; Pagani C; Meli E; Arcaini L; Federico M; Rossi G;
Br J Haematol; 2019 May; 185(4):713-717. PubMed ID: 30793297
[TBL] [Abstract][Full Text] [Related]
32. Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.
Hohloch K; Sahlmann CO; Lakhani VJ; Wulf G; Glass B; Hasenkamp J; Meller J; Riggert J; Trümper L; Griesinger F
Ann Hematol; 2011 Nov; 90(11):1307-15. PubMed ID: 21360108
[TBL] [Abstract][Full Text] [Related]
33. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.
Evens AM; Vanderplas A; LaCasce AS; Crosby AL; Nademanee AP; Kaminski MS; Abel GA; Millenson M; Czuczman MS; Rodriguez MA; Niland J; Zelenetz AD; Gordon LI; Friedberg JW
Cancer; 2013 Oct; 119(20):3662-71. PubMed ID: 23921646
[TBL] [Abstract][Full Text] [Related]
34. Immunochemotherapy with rituximab, vincristine and 5-day cyclophosphamide for heavily pretreated follicular lymphoma.
Lazzarino M; Arcaini L; Orlandi E; Iacona I; Bernasconi P; Calatroni S; Varettoni M; Isa L; Brusamolino E; Bonfichi M; Passamonti F; Burcheri S; Pascutto C; Regazzi M
Oncology; 2005; 68(2-3):146-53. PubMed ID: 16006752
[TBL] [Abstract][Full Text] [Related]
35. The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases.
Rigacci L; Federico M; Martelli M; Zinzani PL; Cavanna L; Bellesi G; Merli F; Alterini R; Petrucci MT; Tani M; Liberati AM; Vitolo U; Pavone V; Cuneo A; Chisesib T; Brugiatelli M;
Leuk Lymphoma; 2003 Nov; 44(11):1911-7. PubMed ID: 14738142
[TBL] [Abstract][Full Text] [Related]
36. Advanced-stage follicular lymphoma in the rituximab era: when should patients receive anthracycline-based chemotherapy?
Pettengell R
Drugs; 2009; 69(13):1727-37. PubMed ID: 19719330
[TBL] [Abstract][Full Text] [Related]
37. Follicular lymphoma: 2011 update on diagnosis and management.
Freedman A
Am J Hematol; 2011 Sep; 86(9):768-75. PubMed ID: 21850659
[TBL] [Abstract][Full Text] [Related]
38. Patients with diffuse large B cell lymphoma in partial response or stable disease after first-line R-CHOP: the prognostic value of the absolute lymphocyte count and impact of autologous stem cell transplantation.
Hung MH; Yu YB; Huang YC; Liu HT; Hong YC; Hsiao LT; Liu JH; Gau JP; Chiou TJ; Chen PM; Tzeng CH; Liu CY
Ann Hematol; 2012 Dec; 91(12):1907-15. PubMed ID: 22885989
[TBL] [Abstract][Full Text] [Related]
39. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention.
Esteve J; Escoda L; Martín G; Rubio V; Díaz-Mediavilla J; González M; Rivas C; Alvarez C; González San Miguel JD; Brunet S; Tomás JF; Tormo M; Sayas MJ; Sánchez Godoy P; Colomer D; Bolufer P; Sanz MA;
Leukemia; 2007 Mar; 21(3):446-52. PubMed ID: 17205057
[TBL] [Abstract][Full Text] [Related]
40. Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study.
Martinelli G; Montoro J; Vanazzi A; Andreola G; Liptrott S; Radice D; Negri M; Preda L; Pruneri G; Laszlo D
Hematol Oncol; 2015 Dec; 33(4):129-35. PubMed ID: 25047267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
